HETEROCYCLIC COMPOUND
The invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a hydrate thereof:, wherein X, Y, R1, R2, R3, R4, R5, and R6 are as defined in the specification, for treatment of a disease, disorder or condition associated with NLRP3, including a disease, disorder or condition associated with a heterozygous gain of function mutation in the NLRP3 gene such as cryopyrin-associated periodic syndrome (CAPS)..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 15. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MIKAMI SATOSHI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-15 |
|---|
| Patentnummer: |
WO2024033845 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000766739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000766739 | ||
| 003 | DE-627 | ||
| 005 | 20240315102055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000766739 | ||
| 035 | |a (EPA)WO2024033845 | ||
| 035 | |a (EPA)87762977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MIKAMI SATOSHI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HETEROCYCLIC COMPOUND |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-15 | ||
| 520 | |a The invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a hydrate thereof:, wherein X, Y, R1, R2, R3, R4, R5, and R6 are as defined in the specification, for treatment of a disease, disorder or condition associated with NLRP3, including a disease, disorder or condition associated with a heterozygous gain of function mutation in the NLRP3 gene such as cryopyrin-associated periodic syndrome (CAPS). | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HOMMA MISAKI |4 aut | |
| 700 | 0 | |a HASUI TOMOAKI |4 aut | |
| 700 | 0 | |a TANAKA YUTA |4 aut | |
| 700 | 0 | |a MORIMOTO SHINJI |4 aut | |
| 700 | 0 | |a KIKUCHI FUMIAKI |4 aut | |
| 700 | 0 | |a WANG CHUNXIANG |4 aut | |
| 700 | 0 | |a YUKAWA TAKAFUMI |4 aut | |
| 700 | 0 | |a OHASHI TOMOHIRO |4 aut | |
| 700 | 0 | |a HIDAKA KOSUKE |4 aut | |
| 700 | 0 | |a IMAMURA KEISUKE |4 aut | |
| 700 | 0 | |a TOITA AKINORI |4 aut | |
| 700 | 0 | |a NAKAMURA SHINJI |4 aut | |
| 700 | 0 | |a ITO MASAHIRO |4 aut | |
| 700 | 0 | |a UYGHUR DILHUMAR |4 aut | |
| 700 | 0 | |a DAINI MASAKI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 15. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87762977/publication/WO2024033845A1?q=WO2024033845 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 02 | ||